Author

Ida Viller Tuxen

Observed names: I Viller Tuxen, I. Tuxen, I.E.V. Tuxen, I.V. Tuxen, Ida Elisabeth Viller Tuxen, Ida Tuxen, Ida V. Tuxen, Tuxen, I. V., Tuxen, I. Viller, Tuxen, Ida Viller

Institutions: Copenhagen University Hospital, Rigshospitalet

Observed institutions: University of Copenhagen, Copenhagen University Hospital, Rigshospitalet, Nordsjællands Hospital

OpenAlex ID: A5073724601

Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials

2018 · Ida Viller Tuxen, Kristoffer Staal Rohrberg, et al. · Clinical Cancer Research · 98

High frequency of pathogenic germline variants within homologous recombination repair in patients with advanced cancer

2019 · Birgitte Bertelsen, Ida Viller Tuxen, et al. · npj Genomic Medicine · 78

PDF

Personalized oncology: genomic screening in phase 1

2014 · Ida Viller Tuxen, Lars Jønson, et al. · Apmis · 19

Application of cell-free DNA for genomic tumor profiling: a feasibility study

2019 · Lise B. Ahlborn, Kristoffer S. Rohrberg, et al. · Oncotarget · 16

PDF

Circulating tumor DNA as a marker of treatment response in BRAF V600E mutated non-melanoma solid tumors

2018 · Lise Barlebo Ahlborn, Ida Viller Tuxen, et al. · Oncotarget · 16

PDF

Copenhagen Prospective Personalized Oncology (CoPPO)—impact of comprehensive genomic profiling in more than 2000 patients in a phase I setting

2025 · L. Belcaid, M. Højgaard, et al. · Annals of Oncology · 14

Plasma total cell-free DNA is a prognostic biomarker of overall survival in metastatic solid tumour patients

2019 · Ida Viller Tuxen, Lise Barlebo Ahlborn, et al. · British Journal of Cancer · 14

PDF

Overall survival after CDK4/6 inhibitor dose reduction in women with metastatic breast cancer

2024 · Andreas Bjerrum, Andreas Frederik Henriksen, et al. · BJC Reports · 12

PDF

New pathogenic germline variants identified in mesothelioma

2023 · Laila Belcaid, Birgitte Bertelsen, et al. · Lung Cancer · 10

PDF

Comprehensive analysis of failure to carry out successful genomic profiling in a phase I setting

2024 · L. Belcaid, C. Iden, et al. · ESMO Open · 3

Mutational Landscape Assessed in Tumor Tissue and Circulating Tumor DNA During Treatment of Patients with HER2/ERBB2-Mutated Solid Tumors

2025 · Kristian Egebjerg, Iben Spanggaard, et al. · BMC Cancer · 2

PDF

391P Detrimental effect on overall survival of CDK4/6 inhibitor dose reduction if immortal time bias is considered

2023 · A. Bjerrum, A.F. Henriksen, et al. · Annals of Oncology · 2

PDF

Copenhagen prospective personalized oncology (CoPPO): Genomic profiling to select patients for phase 1 trials

2016 · I.V. Tuxen, C.W. Yde, et al. · Annals of Oncology · 1

PDF

Copenhagen prospective personalized oncology (CoPPO): Sequencing and array-based pipeline for selection of patients to phase 1 studies.

2014 · Ida Elisabeth Viller Tuxen, Eric Santoni-Rugiu, et al. · Journal of Clinical Oncology · 1

Dose to cardiac substructures following contemporary radiotherapy for early breast cancer: evidence from 6,926 patients

2026 · B Boegh Irankunda, N Janett Forbes, et al. · European Heart Journal Supplements

Interpreting TP53 variants: somatic mosaicism and ERCC6L2 -driven clonal evolution

2026 · Amalie Noergaard Andersson, Anna Byrjalsen, et al. · Journal of Medical Genetics

87P Enhancing treatment strategies for metastatic high-grade neuroendocrine neoplasms: Insights from extensive genomic profiling through WES and WGS in a phase I clinical setting

2024 · S.K. Krogshede, I.K. Buhl, et al. · ESMO Open

Abstract C049: Copenhagen Prospective Personalized Oncology (CoPPO) – The utility of using genomic profiling for tailored therapy in a Phase 1 setting

2023 · Laila Belcaid, Martin Hoejgaard, et al. · Molecular Cancer Therapeutics

Supplementary Data Figure S3 from Copenhagen Prospective Personalized Oncology (CoPPO)—Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials